Journal profile · Oncology
Clinical Lung Cancer
ISSN 1525-7304 · eISSN 1938-0690 · Elsevier · UNITED STATES · Bimonthly · Founded 1999
Clinical Lung Cancer: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.78; hybrid open access; APC about USD 3,200; median 109 days to acceptance (103 articles, last 24 months); community-reported acceptance: fairly easy; 198 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Lung Cancer is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment and Lung Cancer Research Studies, together about 61.6% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Antoinette WozniakPublisher website
Editorial board by country: 2 in mainland China (about 3%); most named United States 44, Japan 5, France 5, Mainland China 2, United Kingdom 2 (62 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine25.6%
- Lung Cancer Diagnosis and TreatmentMedicine20.1%
- Lung Cancer Research StudiesMedicine16%
- Cancer Immunotherapy and BiomarkersMedicine6.4%
- Radiomics and Machine Learning in Medical ImagingMedicine2.8%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance2.5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology2.2%
- Colorectal Cancer Treatments and StudiesMedicine2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.78LetPub ·
- Impact factor (publisher)
- 3.9Publisher website ·
- CiteScore 2026-06
- 6.2LetPub ·
- CiteScore (publisher)
- 6.2Publisher website ·
- SJR 2026-06
- 1.36LetPub ·
- SNIP 2026-06
- 0.92LetPub ·
- h-index
- 52LetPub ·
- h-index
- 92OpenAlex ·
- i10-index
- 1,602OpenAlex ·
- 2-year mean citedness
- 2.55OpenAlex ·
- Self-citation rate
- 2.6%LetPub ·
- Share of gold OA articles
- 12.17%LetPub ·
Volume
- Articles per year
- 157LetPub ·
Articles by year OpenAlex count · 3,210 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 111 | 48 | 21 |
| 2025 | 198 | 79 | 393 |
| 2024 | 170 | 68 | 806 |
| 2023 | 161 | 81 | 1,357 |
| 2022 | 151 | 75 | 1,852 |
| 2021 | 169 | 72 | 2,864 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
109 daysMedian, submission to acceptance · P25–P75 73 days – 143 days
- Acceptance to online
- median 3 days (103 articles)
- Submission to online
- median 113 days
- Sample
- 103 articles with submission and acceptance dates (383 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 13 daysPublisher website ·
- First decision after review
- 67 daysPublisher website ·
- Submission to acceptance
- 110 daysPublisher website ·
- Acceptance to publication
- 5 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,200 / EUR 2,990 / GBP 2,560 / JPY 396,900 | — | — | |
| Publisher website | USD 3,390 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 8,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
- Graphical abstract
- Optional
Article types accepted7, with length limits
- brief reportOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…main text ≤ 1,500 words
- case reportpotential impact on clinical practice. Case Reports should be 500–1,500 words in length. Case Series may be up to 3,000 words. Manuscriptmain text ≤ 1,500 words
- commentaryiscussion, and Conclusion. We recommend Commentaries contain 1000-2000 words, 1-2 figures and/or tables, and 15-30 references. Letters tmain text ≤ 2,000 words
- lettertogether. Mechanics: We recommend that letters contain 500-1000 words, and they may contain 1-2 figures and/or tables and 5-15 remain text ≤ 1,000 words
- perspectivesion, and conclusion. We recommend that Perspective articles contain 2000-8000 words, ≤ 7 figures and/or tables, and 45-90 references. Originalmain text ≤ 8,000 words
- reviewOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
- review articleOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…main text ≤ 10,000 words
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1999
- ISSN
- 1525-7304
- Electronic ISSN
- 1938-0690
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Clinical Lung Cancer
What CAS zone is Clinical Lung Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Lung Cancer is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Lung Cancer?
The latest impact factor listed by LetPub is 3.78; CiteScore 6.2, h-index 92.
How long does peer review take at Clinical Lung Cancer?
Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 109 days (interquartile range 73–143 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical Lung Cancer?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 8,000 words; Reference style: Numbered, in order of citation; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical Lung Cancer based?
Of the 62 board members whose country the journal's board page names, 2 (about 3%) are in mainland China; the countries named most often are United States (44), Japan (5) and France (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Lung Cancer?
According to LetPub and DOAJ records, Clinical Lung Cancer is indexed in SCIE and Scopus.
Is Clinical Lung Cancer open access, and what is the APC?
Clinical Lung Cancer is a hybrid journal. For open-access publication: APC about USD 3,200.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .